Drug development is still dogged by attrition, duplication and waste. Oxford University’s Chas Bountra thinks the answer lies in opening up discoveries to everyone
AstraZeneca on expanding its diabetes research franchise
AstraZeneca is hoping to build a strong franchise focused on cardiovascular, renal, and metabolic (CVRM) diseases. The company’s Joris Silon tells us more
After her daughter was diagnosed with a rare disease, Maria Picone used social media listening to find the best ways to manage the condition. Now her company TREND Community is bringing these insights to pharma
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss the fundamental foundations of communications and how pharma can enable better outcomes
Takeda’s Georgia Keresty is one of the only chief operating officers for R&D in the industry. She tells us what it involves and why it has been important in the wake of the Shire acquisition
Rapidly-changing treatment landscapes in diseases like lung cancer pose challenges for medical education providers, who need to be more adaptable than ever